Generated by AI
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. MBX Biosciences is advancing investigational programs built around its proprietary peptide platform to address conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Its pipeline includes canvuparatide, a parathyroid hormone replacement candidate, as well as additional peptide-based assets in clinical and preclinical development. The company’s work centers on designing long-acting therapies intended to improve treatment convenience and expand options in specialty endocrine care. Based in Carmel, Indiana, MBX Biosciences operates in the biotechnology and specialty therapeutics market, where it contributes to the development of targeted medicines for diseases with significant unmet medical needs.
Website11711 North Meridian Street
Carmel, IN, 46032
United States
The latest articles about MBX.
Summary of Jul 26's posts. Generated by AI.
Summary of Sep 22's posts. Generated by AI.
No summary yet.
Summary of Jan 29's posts. Generated by AI.
Investors talking about MBX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.